Leerink Partnrs Increases Earnings Estimates for AC Immune

AC Immune SA (NASDAQ:ACIU) – Equities research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for AC Immune in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.57) per share for the year, up from their prior estimate of ($0.60). The consensus estimate for AC Immune’s current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($0.55) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Stock Performance

NASDAQ:ACIU opened at $2.75 on Friday. The firm has a market cap of $272.09 million, a price-to-earnings ratio of -5.98 and a beta of 1.29. AC Immune has a 52 week low of $2.25 and a 52 week high of $4.98. The firm’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $3.19.

Hedge Funds Weigh In On AC Immune

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new position in AC Immune in the 2nd quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. lifted its holdings in AC Immune by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after buying an additional 7,400 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after buying an additional 3,499 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.